New drug plus standard treatment for advanced bile duct cancer with EGFR
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called becotatug vedotin, added to standard chemotherapy, for advanced bile duct cancer that has a specific protein called EGFR. The goal is to see if this combination helps shrink tumors or slow the cancer better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with bile duct cancer (including cancer of the gallbladder or bile ducts inside or outside the liver) that cannot be removed by surgery or has spread to other parts of the body.
- You have already tried at least one previous chemotherapy treatment for your cancer, and it did not work or stopped working.
- A test on your tumor sample shows that it has a protein called EGFR (this is sometimes called a 'positive' result).
- You are in generally good health and able to take care of yourself (doctors call this 'ECOG 0-1').
- You are willing to use effective birth control during the study and for 8 weeks after the last dose (if you or your partner could become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for advanced bile duct cancer (cholangiocarcinoma) that has not responded to previous treatment. The drugs work with your immune system to attack cancer cells, and may help slow the disease.
This trial tests a new drug combination for advanced bile duct or gallbladder cancer that has not responded to earlier treatments. It aims to see if the combination can shrink tumors and help patients live longer.
This trial tests whether adding the experimental drug becotatug vedotin to standard chemotherapy and radiation therapy can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma. It may help shrink the tumor or slow its growth.
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
This trial tests two immunotherapy drugs for people with advanced bile duct or gallbladder cancer that has EGFR protein and has not responded to earlier treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.